NCT02792179已完成1 期
A Pilot Longitudinal Follow-Up Study of Tau Burden in The Brain of Subjects With Alzheimer's Disease Who Previously Participated in Study BP29409 Using [18F]RO6958948 Positron Emission Tomography
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 4
- 试验地点
- 1
- 主要终点
- Regional Standardized Uptake Value (SUV), as Assessed by the tau PET Brain Scan
研究概览
简要总结
This is a longitudinal, follow-up study in participants with Alzheimer's disease (AD) who previously participated in study BP29409 (NCT02187627). This study is designed to assess the longitudinal change of Tau pathology in the brain of participants with AD using the PET ligand [18F]RO6958948 and to assess the safety and tolerability of PET ligand.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 25 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •AD participants previously scanned with [18F]RO6958948 in Roche Study BP29409
- •Agreement to use highly effective contraception measures
- •Body mass index (BMI) between 18 and 32 Kilograms per square meter (kg/m^2)
- •A study partner able to accompany the participant to all visits and answer questions about the participant
- •In the opinion of investigator, based on the medical history and physical examination, can safely tolerate tracer administration and the scanning procedures
- •Documented positive visual read (as per local procedures for florbetapir or similar procedures for other amyloid tracers) of an amyloid PET scan, which in the opinion of the principal investigator is consistent with a diagnosis of AD
排除标准
- •Exclusion Criteria for All Participants
- •History or presence of any clinically relevant hematological, hepatic, respiratory, cardiovascular, renal, metabolic, endocrine, or central nervous system disease or other medical conditions that are not well controlled, may put the participant at risk, could interfere with the objectives of the study, or make the participant unsuitable for participation in the study for any other reason in the opinion of the principal investigator
- •Clinically relevant pathological findings in physical examination, electrocardiogram, or laboratory values at the screening assessment that could impact participant safety
- •Known history of clinically significant infectious disease including autoimmune deficiency syndrome (AIDS) or serological indication of acute/chronic hepatitis B or C or Human Immuno Virus infection
- •Women of childbearing potential must not be pregnant, or nursing and serum human chorionic gonadotropin (HCG) must be negative at the time of Screening Visit 1, and urine HCG must be negative on all subsequent visits
- •Loss or donation of more than 450 milliliters (mL) blood in the 4 months before screening or donation of plasma within 14 days of screening
- •Unsuitable veins for repeated venipuncture
- •History of drug or alcohol abuse or positive result from urine screen for drugs of abuse
- •Have received an investigational medication within the last 3 months or 5 times the elimination half-life, whichever is longer, prior to enrollment Exclusion Criteria Related to Trial Procedures
- •Has had or is planning to have exposure to ionizing radiation that in combination with the study-related tracer administrations and scanning procedures would result in a cumulative exposure that exceeds the recommended annual exposure limit
- •Presence of pacemakers; aneurysm clips; artificial heart valves; ear implants; foreign metal objects in the eyes, skin, or body, or any other circumstance that would contraindicate a magnetic resonance imaging (MRI) scan
- •History of, or suffers from, claustrophobia or feels that he or she will be unable to lie still on their back in the MRI or PET scanner
- •Has received treatment that targeted amyloid-beta or tau within the last 24 months
研究组 & 干预措施
[18F]RO6958948
Experimental
Each participant will receive a single intravenous (IV) dose of [18F]RO6958948 and a single PET scan approximately 9-24 months after the baseline scan (in Study BP29409).
干预措施: [18F]RO6958948 (Drug)
结局指标
主要结局
Regional Standardized Uptake Value (SUV), as Assessed by the tau PET Brain Scan
时间窗: Day 1
Change in SUV for Different Brain Regions
时间窗: Baseline to approximately 24 months
Change in SUVR for Different Brain Regions
时间窗: Baseline to approximately 24 months
Regional Standardized Uptake Value Ratios (SUVR), as Assessed by the Tau PET Brain Scan
时间窗: Day 1
次要结局
- Percentage of Participants with Adverse Events(Screening to 7-14 days after Tau PET scan (Up to approximately 7 weeks))
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
A Long Term Extension Study to Assess the Safety of TB006 in Participants With Alzheimer's DiseaseAlzheimer's DiseaseNCT05476783TrueBinding, Inc.119
Unknown
不适用
A Direct Comparative Study of Tau Tracer in Patients With Alzheimer's DiseaseAlzheimer DiseaseNCT05326009Xuanwu Hospital, Beijing60
已完成
2 期
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's DiseaseAlzheimer's DiseaseNCT01227564Pfizer63
Unknown
不适用
Follow-up Study of the Alzheimer's Disease Anti-Inflammatory Prevention TrialAlzheimer DiseaseDementiaNCT01417130Seattle Institute for Biomedical and Clinical Research1,650
已完成
不适用
Alzheimer's disease, cognition and cerebrospinal fluid: Are they associated?Effect of anaesthesia and surgery on cognitionCerebrospinal fluid (CSF) predictors of cognitive change and Alzheimer's diseaeAnaesthesiology - AnaestheticsNeurological - Alzheimer's diseaseMental Health - Studies of normal psychology, cognitive function and behaviourAlzheimer's DiseaseACTRN12612000493842St. Vincent's Hospital54